A private equity consortium sold a consolidated radiology network for $2.4 billion this week, the largest healthcare IT exit recorded in Q1 2025 and a clean multiple on capital deployed during the pandemic consolidation wave. The buyer's identity remains undisclosed, though the sale structure and timing suggest another institutional healthcare investor rather than a strategic acquirer. The transaction clears at roughly 12-14x trailing EBITDA, based on comparable imaging network margins, a premium to the 9-11x range that defined radiology rollups in 2022.

The network operates across multiple states with a mix of hospital contracts, freestanding imaging centers, and teleradiology interpretation services. Revenue is split roughly 60% diagnostic imaging and 40% interventional procedures, a balance that insulates the asset from pure-volume reimbursement cuts. The seller, which entered the investment between 2019 and 2021, rode tailwinds from hospital outsourcing trends and radiologist shortages that made consolidated networks essential infrastructure. The exit comes eighteen months after the consortium refinanced the platform at a $1.8 billion enterprise value, suggesting the buyer paid a 33% premium to that earlier mark.

This matters because radiology consolidation has been a mixed story since 2022. Reimbursement cuts for advanced imaging—particularly MRI and CT—have compressed margins at standalone centers, while hospital systems have clawed back some outsourced contracts to rebuild in-house capacity. Yet this exit proves that well-run networks with diversified payer mix and interventional capabilities still command institutional pricing. The premium paid here reflects two realities: the scarcity of scaled, profitable radiology platforms and the structural shortage of subspecialty radiologists, which makes network contracts stickier than commodity imaging. Allocators should note that healthcare services exits above $1 billion have been rare this cycle, with only four comparable transactions in the past twelve months.

The timing also matters. Hospital capital budgets are under pressure, which typically accelerates outsourcing of non-core services like radiology. Meanwhile, private credit markets have reopened for healthcare services buyouts after a quiet 2023, and this transaction likely benefited from competitive tension between direct lenders and traditional bank syndicates. The $2.4 billion price implies the buyer secured financing at roughly 6.5-7.0x debt-to-EBITDA, aggressive but not reckless for a contracted revenue base. If the buyer is another PE firm, expect a secondary consolidation phase: bolt-on acquisitions of regional imaging groups and tuck-ins of AI-enabled diagnostic tools to drive margin expansion.

Operators and allocators should watch for follow-on M&A in the radiology sector over the next six months. This exit will reset valuation expectations for mid-market imaging networks, particularly those with interventional or subspecialty radiology capabilities. Hospital outsourcing contracts in the $50-150 million revenue range are likely to see increased buyer competition, and smaller rollups may accelerate their own sale processes to capture the valuation momentum. Additionally, watch for the buyer's identity disclosure within 30-45 days via regulatory filings; if it's a strategic healthcare system rather than financial sponsor, that signals a different thesis—vertical integration rather than financial engineering.

The transaction closes at a moment when healthcare services exits have been scarce and pricing uncertain. A $2.4 billion radiology exit, at a premium to recent comps, is the market's answer to whether imaging infrastructure still commands institutional capital. It does.